Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

A team of researchers has identified critical biomarkers that can predict disability worsening in people with multiple ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening ...

Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO ...

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...

‘Early treatment with high-efficacy #multiplesclerosis drugs like ocrelizumab, rituximab, or natalizumab can improve ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...